The annual fee that you pay to the fund company for managing your investment. The lower the expense ratio, the better. This is not an investment recommendation.

Dividends

0.27%Dividend Yield

Dec 25

$0.41

Sep 25

$0.03

Jun 25

$0.01

Mar 25

$0.01

Dec 24

10Y Growth

5.82%

5Y Growth

46.41%

3Y Growth

153.6%

1Y Growth

-39.64%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow XBI. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

iShares Biotechnology

IBB

Mkt Cap0

iShares Nasdaq Biotechnology ETF is a direct competitor, focusing on biotechnology and pharmaceuticals listed on the NASDAQ, similar to XBI's focus on the biotech sector.

VanEck Biotech

BBH

Mkt Cap0

VanEck Vectors Biotech ETF specifically targets the biotech industry, making it a close competitor to XBI with a focus on large-cap biotech companies.

First Trust NYSE Arca Biotechnology Index Fund

FBT

Mkt Cap0

First Trust NYSE Arca Biotechnology Index Fund is another biotech-focused ETF, competing with XBI by investing in companies across various market caps in the biotech sector.

Invesco Biotechnology & Genome

PBE

Mkt Cap0

Invesco Dynamic Biotechnology & Genome ETF competes with XBI by investing in biotech and genome companies, offering a dynamic approach to the biotech industry.

ALPS Medical Breakthroughs

SBIO

Mkt Cap0

ALPS Medical Breakthroughs ETF focuses on small- and mid-cap companies in the biotech and pharmaceutical sectors, competing with XBI's broader biotech focus.

Direxion Daily S&P Biotech Bull 3X

LABU

Mkt Cap0

Direxion Daily S&P Biotech Bull 3X Shares offers leveraged exposure to the biotechnology sector, competing with XBI by targeting similar companies but with a leveraged approach.

Direxion Daily S&P Biotech Bear 3X

LABD

Mkt Cap0

Direxion Daily S&P Biotech Bear 3X Shares is the inverse of LABU, offering leveraged inverse exposure to the biotech sector, and competes with XBI by targeting investors looking for inverse biotech exposure.

Principal Healthcare Innovators

BTEC

Mkt Cap0

Principal Healthcare Innovators Index ETF focuses on early-stage small- and mid-cap healthcare companies, including biotech, competing with XBI's investment in biotech innovation.

Virtus Biotech

BBP

Mkt Cap0

Virtus LifeSci Biotech Products ETF competes with XBI by focusing on companies with one or more drugs in Phase II or Phase III FDA clinical trials, targeting a specific niche within the biotech sector.

Virtus Biotech Clinical Trials

BBC

Mkt Cap0

Virtus LifeSci Biotech Clinical Trials ETF is similar to BBP but focuses on companies in clinical trials, making it a competitor to XBI by targeting a specific investment strategy within the biotech industry.

Holdings

Regions

Sectors

About

The State Street SPDR S&P Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index (the "Index")Seeks to provide exposure to the Biotechnology segment of the S&P TMI, which comprises the following sub-industries: BiotechnologySeeks to track a modified equal weighted index which provides the potential for unconcentrated industry exposure across large, mid and small cap stocksAllows investors to take strategic or tactical positions at a more targeted level than traditional sector based investing

CEO

Country

United States

ISIN

US78464A8707

Listings

0 Comments

Share your thoughts

FAQ

What is State Street SPDR S&P Biotech stock price today?▼

The current price of XBI is $135.92 USD — it has increased by +1.59% in the past 24 hours. Watch State Street SPDR S&P Biotech stock price performance more closely on the chart.

What is State Street SPDR S&P Biotech stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange State Street SPDR S&P Biotech stocks are traded under the ticker XBI.

Is State Street SPDR S&P Biotech stock price growing?▼

XBI stock has risen by +5.16% compared to the previous week, the month change is a +5.27% rise, over the last year State Street SPDR S&P Biotech has showed a +75.73% increase.

Does State Street SPDR S&P Biotech pay dividends?▼

Yes, XBI dividends are paid quarterly. The last dividend per share was 0.41 USD. As of today, Dividend Yield (FWD)% is 0.27%.

In which sector is State Street SPDR S&P Biotech located?▼

State Street SPDR S&P Biotech operates in the Other sector.

When did State Street SPDR S&P Biotech complete a stock split?▼

The last stock split for State Street SPDR S&P Biotech was on September 11, 2015 with a ratio of 3:1.